Individual state nursing approvals Colibri Healthcare, LLC is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. In addition to states that accept courses offered by ANCC Accredited Providers, Colibri Healthcare, LLC is an approved Provider of continuing education in nursing by: Alabama Board of Nursing, Provider #ABNP1418 (valid through February 5, 2025); Arkansas State Board of Nursing, Provider #50-4007; California Board of Registered Nursing, Provider #CEP17480 (valid through January 31, 2024); California Board of Vocational Nursing and Psychiatric Technicians (LVN Provider #V15058, PT Provider #V15020; valid through December 31, 2023); District of Columbia Board of
Nursing, Provider #50-4007; Florida Board of Nursing, Provider #50-4007; Georgia Board of Nursing, Provider #50-4007; Kentucky Board of Nursing, Provider #7-0076 (valid through December 31, 2023; CE Broker Provider #50-4007); Michigan Board of Nursing, Provider #50-4007; Mississippi Board of Nursing, Provider #50- 4007; New Mexico Board of Nursing, Provider #50-4007; North Dakota Board of Nursing, Provider #50-4007; South Carolina Board of Nursing, Provider #50-4007; and West Virginia Board of Registered Nurses, Provider #50-4007. This CE program satisfies the Massachusetts States Board’s regulatory requirements as defined in 244 CMR5.00: Continuing Education.
Activity director Deborah Martin, DNP, MBA, RN, NE-BC, FACHE, Director of Learning Innovation Colibri Healthcare, LLC Disclosures Resolution of conflict of interest
Sponsorship/commercial support and non-endorsement It is the policy of Colibri Healthcare, LLC not to accept commercial support. Furthermore, commercial interests are prohibited from distributing or providing access to this activity to learners.
In accordance with the ANCC Standards for Commercial Support for continuing education, Colibri Healthcare, LLC implemented mechanisms prior to the planning and implementation of the continuing education activity, to identify and resolve conflicts of interest for all individuals in a position to control content of the course activity. Disclaimer The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative
to diagnostic and treatment options of a specific patient’s medical condition.
©2023: All Rights Reserved. Materials may not be reproduced without the expressed written permission or consent of Colibri Healthcare, LLC. The materials presented in this course are meant to provide the consumer with general information on the topics covered. The information provided was prepared by professionals with practical knowledge of the areas covered. It is not meant to provide medical, legal, or professional advice. Colibri Healthcare, LLC recommends that you consult a medical, legal, or professional services expert licensed in your state. Colibri Healthcare, LLC has made all reasonable efforts to ensure that all content provided in this course is accurate and up to date at the time of printing, but does not represent or warrant that it will apply to your situation nor circumstances and assumes no liability from reliance on these materials. Quotes are collected from customer feedback surveys. The models are intended to be representative and not actual customers. Course verification All individuals involved have disclosed that they have no No. 241, every reasonable effort has been made to ensure that the content in this course is balanced and unbiased. significant financial or other conflicts of interest pertaining to this course. Likewise, and in compliance with California Assembly Bill
INTRODUCTION
Diabetes is one of the most prevalent diseases in the pediatric population, and the rates of diagnosis are on the rise. Type 1 diabetes mellitus (T1DM), a subtype of diabetes, is the most common type in children, and specialized training is required for management. New diagnoses require individualized treatment plans accompanied by extensive education in order for patients and their families to be successful in achieving glycemic control. The disease is a lifelong diagnosis and initiating excellent care as early as possible may help prevent complications and improve Case study: Rob Rob is an eight-year-old male who presents to the pediatric clinic for a well visit. His mother reports he “hasn’t been himself” lately. He has been drinking a lot of water and urinating more frequently in the past few weeks. Rob’s medical history includes atopic dermatitis, which is well managed with emollients and occasional topical corticosteroids. He takes a multivitamin daily and is not currently on any other medications. He has no reported medication or food allergies. The only notable element
quality of life for pediatric patients as they age. Physicians, nurses, and pharmacists are all well positioned to serve in the management of pediatric patients with T1DM. In this course, the healthcare professional will learn about the diagnosis and management of T1DM, including special considerations related to insulin dosing and nutritional management. Pediatric educational and psychosocial challenges will also be addressed along with guidance for management. of his family history is a paternal grandfather with diabetes. His height, weight, blood pressure, heart rate, and respiratory rate are all within normal limits for his age. After checking his growth chart, you notice he has lost approximately eight pounds since a recent sick visit about three months prior. His mother cannot identify a cause for this weight loss, as his diet and exercise habits have remained consistent. ● Oral glucose tolerance test (glucose load) with two-hour plasma glucose ≥200 mg/dL ● Random plasma glucose ≥200 mg/dL with classic hyperglycemic symptoms While these criteria are standard, they do not provide the complete picture of the underlying pathophysiology of each
OVERVIEW OF PEDIATRIC DIABETES
According to the American Diabetes Association (ADA) 2022 criteria, diabetes is defined by one of the following criteria (ADA et al., 2022a). ● Hemoglobin A1c (HbA1c) ≥6.5% ● Fasting (no caloric intake for ≥8 hours) plasma glucose ≥126 mg/dL
Page 98
Book Code: AUS3024
EliteLearning.com/Nursing
Powered by FlippingBook